Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...

Drug maker Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies , a biopharmaceutical company, Bloomberg ...

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...

Intra-Cellular Therapies stock leapt more than 30% Monday morning, after Johnson & Johnson agreed to buy the ...

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its ...

Nvidia pushes back on new artificial-intelligence regulations, Tesla stock trades lower, Moderna issues weak revenue guidance ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire ...

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...

J&J said it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into ...